Fast-moving CGT space still facing same challenges

6 March 2024
gene_genetic_test_biotech_biomarker_lab_research_2022_big

Progress is happening in the cell and gene therapies (CGT) space - but that does not mean that the challenges that have held it back are about to disappear.

Regulatory barriers and cost concerns continue to hamper their widespread adoption, according to the data and analytics company GlobalData, in its overview of the space.

An analysis of GlobalData’s Drug Database reveals that over the past decade, a total of 14 cell and gene therapies were approved across various therapy areas in the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology